• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Structural insights of catalytic mechanism in mutant pyrazinamidase of .结核分枝杆菌突变吡嗪酰胺酶催化机制的结构见解。
J Biomol Struct Dyn. 2021 Jun;39(9):3172-3185. doi: 10.1080/07391102.2020.1761879. Epub 2020 May 12.
2
Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the gene in clinical isolates of .从吡嗪酰胺的分子机制到与临床分离株中 基因相关的突变吡嗪酰胺酶的见解。
J Biomol Struct Dyn. 2024 Jan-Feb;42(2):759-765. doi: 10.1080/07391102.2023.2195002. Epub 2023 Apr 25.
3
Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N.三种吡嗪酰胺酶突变体 N11K、P69T 和 D126N 的吡嗪酰胺耐药机制的研究进展。
J Chem Inf Model. 2019 Jan 28;59(1):498-508. doi: 10.1021/acs.jcim.8b00525. Epub 2018 Dec 7.
4
Structural dynamics behind variants in pyrazinamidase and pyrazinamide resistance.吡嗪酰胺酶和吡嗪酰胺耐药性变异背后的结构动力学。
J Biomol Struct Dyn. 2020 Jul;38(10):3003-3017. doi: 10.1080/07391102.2019.1650113. Epub 2019 Aug 5.
5
Revelation of enzyme activity of mutant pyrazinamidases from Mycobacterium tuberculosis upon binding with various metals using quantum mechanical approach.利用量子力学方法揭示结核分枝杆菌突变吡嗪酰胺酶与各种金属结合时的酶活性。
Comput Biol Chem. 2019 Dec;83:107108. doi: 10.1016/j.compbiolchem.2019.107108. Epub 2019 Aug 16.
6
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.巴基斯坦开伯尔-普赫图赫瓦省结核分枝杆菌分离株中吡嗪酰胺耐药性及 pncA 基因突变。
BMC Infect Dis. 2019 Feb 6;19(1):116. doi: 10.1186/s12879-019-3764-2.
7
pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.pncA突变作为结核分枝杆菌对吡嗪酰胺耐药的主要机制:单一耐药菌株在加拿大魁北克的传播
Antimicrob Agents Chemother. 2000 Mar;44(3):528-32. doi: 10.1128/AAC.44.3.528-532.2000.
8
Estimation of pyrazinamidase activity using a cell-free synthesis of pnca and its association with pyrazinamide susceptibility in .使用无细胞合成对硝基苯甲酸酯(pnca)估计吡嗪酰胺酶活性及其与吡嗪酰胺敏感性的关联。 (原文中“in.”后面似乎缺少内容)
Int J Mycobacteriol. 2018 Jan-Mar;7(1):16-25. doi: 10.4103/ijmy.ijmy_187_17.
9
Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.堪萨斯分枝杆菌的吡嗪酰胺酶活性降低及其对抗结核药物吡嗪酰胺的天然耐药性。
Antimicrob Agents Chemother. 1999 Mar;43(3):537-42. doi: 10.1128/AAC.43.3.537.
10
Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.分枝杆菌中吡嗪酰胺耐药机制:除缺乏吡嗪酰胺酶活性外,摄取缺乏的重要性。
Microbiology (Reading). 1999 Jun;145 ( Pt 6):1359-1367. doi: 10.1099/13500872-145-6-1359.

引用本文的文献

1
A computational perspective on the dynamic behaviour of recurrent drug resistance mutations in the pncA gene from .来自……的pncA基因中复发性耐药突变动态行为的计算视角
RSC Adv. 2021 Jan 11;11(4):2476-2486. doi: 10.1039/d0ra09326b. eCollection 2021 Jan 6.
2
Structural and Dynamic Insights into the W68L, L85P, and T87A Mutations of Inducing Resistance to Pyrazinamide.对吡嗪酰胺耐药性诱导的 W68L、L85P 和 T87A 突变的结构和动态洞察。
Int J Environ Res Public Health. 2022 Jan 30;19(3):1615. doi: 10.3390/ijerph19031615.
3
Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe Ion in Gene of to Decipher the Mechanism of Resistance to Pyrazinamide.深入了解结核分枝杆菌基因中突变诱导的构象变化和铁离子重排以破译对吡嗪酰胺的耐药机制。
Front Mol Biosci. 2021 May 20;8:633365. doi: 10.3389/fmolb.2021.633365. eCollection 2021.
4
Computational analysis of deleterious single nucleotide polymorphisms in catechol O-Methyltransferase conferring risk to post-traumatic stress disorder.儿茶酚-O-甲基转移酶中有害单核苷酸多态性与创伤后应激障碍风险关系的计算分析
J Psychiatr Res. 2021 Jun;138:207-218. doi: 10.1016/j.jpsychires.2021.03.048. Epub 2021 Mar 31.

结核分枝杆菌突变吡嗪酰胺酶催化机制的结构见解。

Structural insights of catalytic mechanism in mutant pyrazinamidase of .

机构信息

College of Life Sciences and Biotechnology, The State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, China.

Peng Cheng Laboratory, Shenzhen, Guangdong, P.R China.

出版信息

J Biomol Struct Dyn. 2021 Jun;39(9):3172-3185. doi: 10.1080/07391102.2020.1761879. Epub 2020 May 12.

DOI:10.1080/07391102.2020.1761879
PMID:32340563
Abstract

Pyrazinamidase (PZase) is a member of Fe-dependent amidohydrolases that activates pyrazinamide (PZA) into active pyrazinoic acid (POA). PZA, a nicotinamide analogue, is an essential first-line drug used in (Mtb) treatment. The active form of PZA, POA, is toxic and potently inhibits the growth of latent Mtb, which makes it possible to shorten the conventional 9-month tuberculosis treatment to 6 months. In this study, an extensive molecular dynamics simulation was carried out to the study the resistance mechanism offered by the three mutations Q10P and D12A and G97D. Our results showed that two regions Gln10-His43, Phe50-Gly75 are profoundly affected by these mutations. Among the three mutations, Q10P and D12A mutations strongly disturb the communication among the catalytic triad (Asp8, Lys98 and Cys138). The oxyanion hole is formed between the backbone nitrogen atoms of A134 and C138 which stabilizes the hydroxyl anion of nicotinamide. The D12A mutation greatly disturbs the oxyanion hole formation followed by the Q10P and G97D. Our results also showed that these mutations destabilize the interaction between Fe ion and Asp49, His51, His57 and His71. The binding pocket analysis showed that these mutations increase the cavity volume, which results in loose binding of PZA. MMGBSA analyzes have shown that these mutations reduce the binding affinity to the PZA drug. Our results may provide useful information for the design of new and effective PZase inhibitors based on structural information of WT and mutant PZases.Communicated by Ramaswamy H. Sarma.

摘要

吡嗪酰胺酶 (PZase) 是一种依赖铁的酰胺水解酶,能够将吡嗪酰胺 (PZA) 激活为活性吡嗪酸 (POA)。PZA 是一种烟酰胺类似物,是治疗结核分枝杆菌 (Mtb) 的一线基本药物。PZA 的活性形式 POA 具有毒性,能够强烈抑制潜伏 Mtb 的生长,这使得将传统的 9 个月结核病治疗缩短至 6 个月成为可能。在这项研究中,我们进行了广泛的分子动力学模拟,以研究由三个突变 Q10P、D12A 和 G97D 提供的耐药机制。我们的研究结果表明,两个区域 Gln10-His43、Phe50-Gly75 受到这些突变的深刻影响。在这三个突变中,Q10P 和 D12A 突变强烈干扰催化三联体 (Asp8、Lys98 和 Cys138) 之间的通讯。氧阴离子空洞在 A134 和 C138 的骨架氮原子之间形成,稳定了烟酰胺的羟基阴离子。D12A 突变极大地干扰了氧阴离子空洞的形成,随后是 Q10P 和 G97D。我们的结果还表明,这些突变使 Fe 离子与 Asp49、His51、His57 和 His71 的相互作用不稳定。结合口袋分析表明,这些突变增加了空腔体积,导致 PZA 的结合松散。MMGBSA 分析表明,这些突变降低了与 PZA 药物的结合亲和力。我们的研究结果可能为基于 WT 和突变 PZase 的结构信息设计新的有效的 PZase 抑制剂提供有用信息。